Tirzepatide captured 41% of new GLP-1 starts in 12 months, while semaglutide's SELECT cardiovascular label reshapes a $22B US formulary landscape.

The US Type 2 Diabetes market spans GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors and insulin, covering an estimated 38.4 million US adults with total drug spend exceeding $22 billion in 2023. Tirzepatide (Mounjaro/Zepbound, Eli Lilly) achieved 41% of new GLP-1 prescriptions within 12 months of launch, driven by superior A1c reduction of 2.0 to 2.3% at maximum dose and 15 to 22% weight loss from the SURPASS trials.

Semaglutide's SELECT cardiovascular outcome trial, showing a 20% MACE reduction in overweight and obese adults without Type 2 Diabetes, is reshaping payer access policies beyond glycemic control. Major commercial payers are building new step-edit pathways requiring an SGLT2 trial before GLP-1 access in some populations. IRA Medicare negotiation targets SGLT2 inhibitors, empagliflozin and dapagliflozin, for price reduction starting in 2026, adding downstream pricing pressure across the class.

A cardiovascular label, not glycemic data, is now setting the payer access bar.

Five questions this report answers:

Q1 - How is tirzepatide's dual GIP/GLP-1 mechanism translating into formulary preference over semaglutide at major payers?

Q2 - What is the IRA Medicare negotiation exposure for empagliflozin and dapagliflozin through 2028?

Q3 - Which next-generation agents, orforglipron, retatrutide and CagriSema, threaten to displace current class leaders by 2027?

Q4 - How did semaglutide's SELECT trial 20% MACE reduction change payer step-edit design beyond glycemic control?

Q5 - What SGLT2 patent expiry and generic timeline pressures are reshaping step-edit requirements ahead of GLP-1 access?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#Type2Diabetes #US #CompetitiveIntelligence #AXLRx #GLP1

Live report page:  https://axlrx.ai/type-2-diabetes/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

A one-time $2.125 million gene therapy competes against two chronic SMN2 modifiers, and newborn screening now decides the winner at diagnosis.

Spinal muscular atrophy is a monogenic motor-neuron disease caused by biallelic loss of SMN1, with SMN2 copy number setting severity. Three FDA-approved agents address it by distinct mechanisms: nusinersen (Spinraza, Biogen), an intrathecal antisense oligonucleotide approved December 2016; onasemnogene abeparvovec (Zolgensma, Novartis), a one-time AAV9 gene therapy approved May 2019 for patients under two; and risdiplam (Evrysdi, Roche/PTC), a daily oral approved August 2020 for all ages and types.

The commercial contest turns on two forces. A single $2.125 million gene-therapy infusion competes against therapies billed for life, so payers weigh one-time cure-intent against chronic control based on age and SMN2 copy number. Newborn screening, added to the federal panel in 2018 and covering all 50 states by 2023, now moves roughly 300 new diagnoses a year into a pre-symptomatic window where gene therapy produces near-normal motor development.

The battleground has shifted from rescuing symptomatic infants to treating pre-symptomatic newborns.

Five questions this report answers:

Q1 - How do the three SMA mechanisms differentiate on route, dosing and one-time versus chronic treatment?

Q2 - What does universal newborn screening mean for the competitive map between gene therapy and chronic modifiers?

Q3 - How do one-time gene therapy and lifetime chronic therapy compare on total cost and payer positioning?

Q4 - Why does age under two gate eligibility for the one-time Zolgensma gene therapy?

Q5 - How many new SMA diagnoses does universal newborn screening identify pre-symptomatically each year?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SpinalMuscularAtrophy #US #CompetitiveIntelligence #AXLRx #RareDisease

Live report page:  https://axlrx.ai/spinal-muscular-atrophy/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

  All three UK SMA therapies cleared NICE with confidential pricing, so the 2021 newborn screening programme now decides who gets treated first.

An estimated 1,000 UK patients live with spinal muscular atrophy across all types. The UK added SMA to its national newborn screening programme in 2021, the first such programme in Europe, identifying roughly 25 pre-symptomatic patients per year and routing them to one of 6 specialist centres. NICE has recommended all three approved SMA therapies through confidential Patient Access Scheme agreements: Zolgensma, via the Highly Specialised Technology route (HST15, 2021, expanded to pre-symptomatic patients under HST24); Spinraza (TA588, 2019), an intrathecal option for Types 1-3; and Evrysdi (TA755, 2022), an oral SMN2 modifier families increasingly prefer.

The NHS treatment algorithm is now type- and age-based rather than access-based: Type 1 and NBS-identified pre-symptomatic patients under 2 years route to Zolgensma; Type 2/3 patients choose between nusinersen and risdiplam. All three agents carry confidential PAS pricing, so relative NHS net cost is commercially sensitive, but Zolgensma's cost-effectiveness case for its $2.125 million list price was only accepted under a confidential commercial arrangement negotiated through the HST15 appraisal, later expanded to presymptomatic infants under HST24. Nusinersen remains the default for roughly 300 UK patients, largely adults outside Zolgensma's age/weight eligibility, while risdiplam's oral dosing is winning share by reducing intrathecal procedure burden.

Access is resolved for all three; family and physician preference now decides share.

Five questions this report answers:

Q1 - How is the 2021 newborn screening programme changing first-prescribing decisions for Zolgensma?

Q2 - What confidential PAS pricing structure let Zolgensma's $2.125 million list price clear NICE?

Q3 - Why are UK families increasingly choosing oral risdiplam over intrathecal nusinersen for Type 2/3?

Q4 - How did HST24 expand Zolgensma's NICE recommendation to pre-symptomatic infants in 2023?

Q5 - Why does nusinersen remain the default for roughly 300 UK adult patients?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SpinalMuscularAtrophy #UK #CompetitiveIntelligence #AXLRx #NICE #GeneTherapy

Live report page:  https://axlrx.ai/spinal-muscular-atrophy/uk/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Three SMA mechanisms are formulary-listed in GCC, and newborn screening is generating 60-80 new gene-therapy candidates a year.

SMA incidence in GCC is estimated at 1 in 6,000 to 8,000 live births, well above the global 1 in 10,000 rate, driven by consanguinity raising the frequency of homozygous SMN1 deletion. Saudi Arabia added SMA to its national newborn-screening programme in 2021, among the first GCC states to do so, with the UAE and Qatar following by 2023; screening coverage reached an estimated 90% of Saudi births, 85% in the UAE, and 75% in Qatar by mid-2024, while Oman, Bahrain, and Kuwait remain below 50%. Newborn-screening-identified pre-symptomatic infants are now being treated at KAMC, KFSH&RC, Sidra Medicine, and SKMC.

All three SMA mechanisms are registered and accessible across GCC. Onasemnogene abeparvovec (Zolgensma), SFDA-registered in 2021, is NPHC-covered for Type 1 and pre-symptomatic newborn-screening-identified infants; NPHC and MOH UAE have negotiated outcomes-based rebate arrangements tied to a 24-month motor-milestone, bringing GCC list price to an estimated $1.5-1.8 million versus $2.125 million in the US. An estimated 60-80 Zolgensma cases occur across GCC annually. Nusinersen (Spinraza), SFDA-registered since 2017, remains standard of care for older, symptomatic Type 2/3 patients, while risdiplam (Evrysdi) is gaining share among families who prefer a daily oral to intrathecal dosing.

Outcomes-based rebates now decide Zolgensma's real GCC price, not the list price alone.

Five questions this report answers:

Q1 - What are the terms of the NPHC outcomes-based rebate arrangement for Zolgensma?

Q2 - How does SMA newborn-screening coverage vary by GCC country, and what does the gap mean for Zolgensma volume?

Q3 - What is driving the shift from nusinersen to risdiplam among older Type 2/3 patients?

Q4 - How does newborn screening shape Zolgensma volume across the six GCC states?

Q5 - How is the 24-month motor-milestone assessed and enforced under the rebate contract?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SMA #GCC #Zolgensma #GeneTherapy #RareDisease #MarketAccess

Live report page:  https://axlrx.ai/spinal-muscular-atrophy/gcc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Casgevy and Lyfgenia reset a 100,000-patient US market, yet hydroxyurea, proven decades ago, still reaches only 25-30% of eligible patients.

Sickle cell disease became a gene-therapy market in December 2023, when the FDA approved two one-time autologous therapies for patients aged 12 and older with recurrent vaso-occlusive disease. Casgevy (exagamglogene autotemcel, Vertex/CRISPR Therapeutics) uses CRISPR-Cas9 to edit the BCL11A enhancer and reactivate fetal hemoglobin; in the pivotal CLIMB SCD-121 study, 29 of 30 evaluable patients (97%) were free from severe vaso-occlusive crises for at least 12 months. Lyfgenia (lovotibeglogene autotemcel, bluebird bio) adds an anti-sickling beta-globin gene via a lentiviral vector and carries an FDA boxed warning for hematologic malignancy. Both require weeks of myeloablative conditioning and apheresis, and carry one-time list prices of roughly $2.2M and $3.1M.

Against these curative-intent therapies sits a disease-modifying backbone that remains under-deployed. Generic hydroxyurea, proven decades ago to cut painful crises by about 44%, still reaches only 25-30% of eligible patients. L-glutamine (Endari) and the P-selectin inhibitor crizanlizumab (Adakveo) round out the oral and infused options. The field narrowed in 2024 when Pfizer withdrew voxelotor (Oxbryta) from the market over a safety signal: FDA Drugs@FDA now lists it as discontinued, and it is excluded from this in-market landscape. The commercial contest is therefore two-tiered, a high-cost, logistically demanding gene-therapy duel layered over a legacy backbone with a large, addressable adherence gap.

Curative gene therapy costs millions; the cheap generic backbone still reaches a quarter of patients.

Five questions this report answers:

Q1 - How do Casgevy and Lyfgenia differ on mechanism, efficacy, safety, price, and patient eligibility?

Q2 - Why does generic hydroxyurea still reach only 25-30% of eligible SCD patients?

Q3 - Why was voxelotor (Oxbryta) withdrawn from the market in 2024, and what does that leave in the oral field?

Q4 - What do Casgevy's $2.2M and Lyfgenia's $3.1M one-time list prices mean for payer budgeting?

Q5 - What does Lyfgenia's FDA boxed warning for hematologic malignancy mean for prescriber and patient uptake?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SickleCellDisease #US #CompetitiveIntelligence #AXLRx #GeneTherapy #PharmaMarketAccess

Live report page:  https://axlrx.ai/sickle-cell-disease/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Casgevy's NICE recommendation creates a £300-600 million a year NHS budget event, while Lyfgenia has no UK regulatory status at all.

The UK has an estimated 15,000-17,000 diagnosed sickle cell disease patients, the largest SCD population in Europe, concentrated in London (6,000+), Birmingham, Manchester, Bristol, and Nottingham. NHS newborn screening has covered SCD since 1999, so virtually every UK patient is diagnosed at birth, with roughly 500 new diagnoses per year. Generic hydroxyurea, established as the NHS disease-modifying standard under NICE clinical guideline CG143 and reinforced by NICE quality standard QS58, remains the dominant therapy for patients with 3 or more vaso-occlusive crises per year and the NHS treatment backbone.

Crizanlizumab (Adakveo) was the only novel VOC-prevention agent to reach the NHS beyond hydroxyurea, but the EMA's CHMP recommended revoking its marketing authorisation in May 2023 after the confirmatory STAND trial failed its primary endpoint. Roughly 300 UK patients who had accessed crizanlizumab through NHS England interim funding reverted to hydroxyurea, leaving a commercial gap in VOC prevention. Gene therapy is now the next market event: Casgevy (exa-cel, Vertex/CRISPR Therapeutics), MHRA-approved in November 2023, holds a positive NICE recommendation under TA1044 for patients aged 12 and over. Lyfgenia (bluebird bio) has no UK regulatory status at all: bluebird bio withdrew from the UK/EU market in 2021 and never submitted it to the MHRA or NICE.

One gene therapy is commissioned; its only US rival was never even filed here.

Five questions this report answers:

Q1 - What outcomes-based contracting let Casgevy secure NHS commissioning at over £1.5 million per patient?

Q2 - Which NHS centres are being designated as SCD gene therapy hubs under TA1044?

Q3 - With crizanlizumab withdrawn, what pharmacological option follows hydroxyurea for VOC prevention?

Q4 - How does NICE clinical guideline CG143 define the hydroxyurea eligibility threshold?

Q5 - Why did bluebird bio never submit Lyfgenia to the MHRA or NICE?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SickleCellDisease #UK #CompetitiveIntelligence #AXLRx #NICE #GeneTherapy

Live report page:  https://axlrx.ai/sickle-cell-disease/uk/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

GCC's roughly 140,000 Saudi Arabia SCD patients depend on a 25-year-old generic after both novel disease-modifiers hit regulatory trouble since 2023.

GCC carries an estimated 200,000-250,000 sickle cell disease patients, with Saudi Arabia alone accounting for roughly 140,000, among the highest national disease burdens outside sub-Saharan Africa. Carrier frequency reaches 6-7% in Saudi Arabia's Eastern Province and 10-15% in Bahrain and Oman. National premarital screening programmes operate in Saudi Arabia, the UAE, Qatar, and Bahrain, and are measurably reshaping epidemiology: carrier-carrier marriages are declining 15-20% annually in Saudi Arabia. Hydroxyurea, generic since 1998, remains the region's only disease-modifying therapy with a stable market position, prescribed to an estimated 35-40% of eligible patients, a higher rate than the US's 25-30%.

Both novel disease-modifying agents that reached GCC registration have since encountered regulatory setbacks. Crizanlizumab (Adakveo), SFDA-registered in 2021, was withdrawn from the EU market in 2023 after its confirmatory trial failed, leaving its GCC formulary position under MOH review. Voxelotor (Oxbryta) was voluntarily withdrawn by the FDA in 2024 for the same reason, and most GCC centres are now transitioning patients off it. Gene therapies Casgevy and Lyfgenia, FDA- and EMA-approved in December 2023, are not yet SFDA- or MOHAP-registered as of mid-2024, though KFSH&RC and SKMC are building cell-therapy capability that could accommodate them by 2025-2026.

Two novel disease-modifiers failed just as gene therapy access remains 18-24 months away.

Five questions this report answers:

Q1 - What is the current MOH/SFDA formulary status of crizanlizumab and voxelotor after their withdrawals?

Q2 - When are Casgevy and Lyfgenia likely to reach SFDA/MOHAP registration in the GCC?

Q3 - How are national premarital screening programmes changing the SCD patient pipeline in KSA, UAE, Qatar, and Bahrain?

Q4 - Why have both novel SCD disease-modifying agents run into regulatory trouble since 2023?

Q5 - Which GCC centres are building the cell-therapy infrastructure to deliver Casgevy and Lyfgenia?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SickleCellDisease #GCC #GeneTherapy #RareDisease #Hydroxyurea #MarketAccess

Live report page:  https://axlrx.ai/sickle-cell-disease/gcc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Bimekizumab hit PASI 90 in 85% of patients versus 50% for ustekinumab, resetting psoriasis's efficacy bar across six competing mechanisms.

The moderate-to-severe plaque psoriasis market is no longer contested on PASI 75. Bimekizumab (Bimzelx), which blocks both IL-17A and IL-17F, delivered PASI 90 in 85% of patients at week 16 in BE VIVID versus 50% for ustekinumab. IL-23p19 agents guselkumab (Tremfya, VOYAGE 1: PASI 90 73.3% vs adalimumab 49.7%) and risankizumab (Skyrizi, UltIMMa: PASI 90 75.3% vs ustekinumab 42%) pair that clearance with quarterly (q12w) maintenance dosing, which has made risankizumab the volume leader in the class.

The older mechanisms are now the defended flank. Ustekinumab (IL-12/23) and adalimumab (TNF) both face US biosimilar erosion, and the two remaining branded battlegrounds are convenience and route: deucravacitinib (Sotyktu), the first oral selective TYK2 inhibitor, cleared PASI 75 in 58.4% at week 16 versus 35.1% for apremilast and 12.7% for placebo in POETYK PSO-1, positioning it as the oral that finally beats apremilast rather than another injectable.

Once PASI 90 is table stakes, dosing interval decides who wins share.

Five questions this report answers:

Q1 - Does incremental clearance beyond PASI 90 still move share, or has dosing interval taken over?

Q2 - Can oral deucravacitinib expand the biologic-eligible pool, or does it mainly replace apremilast?

Q3 - Where does branded defense hold as ustekinumab and adalimumab biosimilars enter the US market?

Q4 - What do BE VIVID's 85% and UltIMMa's 75.3% PASI 90 rates mean for prescriber choice?

Q5 - How did deucravacitinib's 58.4% PASI 75 rate compare with apremilast's 35.1% in POETYK PSO-1?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#Psoriasis #US #CompetitiveIntelligence #AXLRx #Dermatology #PharmaMarketAccess

Live report page:  https://axlrx.ai/psoriasis/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Avalglucosidase alfa's NICE recommendation is settled, so NHS conversion speed, not cost-effectiveness, now gates the switch from alglucosidase alfa.

An estimated 200 UK patients, infantile- and late-onset combined, receive enzyme replacement therapy for Pompe disease, commissioned by NHS England Highly Specialised Services via clinical commissioning policy at 6-8 specialist metabolic disease centres, including Guy's and St Thomas', Manchester, Birmingham, and Queen Elizabeth Edinburgh. Infantile-onset patients begin alglucosidase alfa (Lumizyme/Myozyme, Sanofi) directly from newborn-screening confirmation, while late-onset patients require documented FVC decline or functional impairment before ERT initiation is authorised. Alglucosidase alfa remains the dominant, NHS-commissioned ERT: roughly 180 of the estimated 200 UK Pompe patients are on it today.

Nexviazyme (avalglucosidase alfa, Sanofi) is NICE-recommended as the first switch candidate (TA821, published August 2022, with a commercial arrangement already in place): the COMET trial showed a 23.5-metre 6-minute-walk-test improvement against a 13.2-metre decline for alglucosidase alfa, alongside better forced vital capacity preservation. With the appraisal and commercial arrangement already settled, the constraint on switching late-onset patients is now the pace of NHS conversion, not a pending cost-effectiveness decision. Pombiliti + Opfolda (Amicus), which showed a 20.8-metre 6MWT improvement in switch patients in the PROPEL trial, sits further back in the NICE appraisal queue and is currently accessible only via named-patient exceptional commissioning.

Cost-effectiveness is settled; the constraint now is how fast NHS centres convert patients.

Five questions this report answers:

Q1 - How quickly will NHS centres convert eligible patients from alglucosidase alfa to avalglucosidase alfa?

Q2 - What inadequate-response criteria will gate NHS switching to avalglucosidase alfa or Pombiliti + Opfolda?

Q3 - Where does Pombiliti + Opfolda sit in the NICE queue behind avalglucosidase alfa's TA821?

Q4 - How did COMET's 23.5-metre versus 13.2-metre 6-minute-walk result favor avalglucosidase alfa?

Q5 - Why does alglucosidase alfa still cover 180 of the UK's 200 Pompe patients?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PompeDisease #UK #CompetitiveIntelligence #AXLRx #NICE #RareDisease

Live report page:  https://axlrx.ai/pompe-disease/uk/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/

Lumizyme has been NPHC's covered standard since 2006, and next-generation ERT switch criteria still don't exist.

Pompe disease incidence in GCC is estimated at 1 in 20,000 to 30,000 births, elevated above the global 1 in 40,000 rate by consanguinity, with classic infantile-onset disease concentrated in consanguineous families and late-onset cases managed through adult metabolic disease services at KFSH&RC, KAMC, and AUH. Saudi Arabia added Pompe to its newborn-screening panel in 2021, creating a pre-symptomatic infantile-onset pipeline that anchors alglucosidase alfa as first treatment before any next-generation competitor can enter. NPHC covers enzyme replacement therapy for both infantile- and late-onset disease, and total treated patients across GCC number an estimated 80-120.

Avalglucosidase alfa (Nexviazyme), SFDA-registered in 2022, demonstrated superior six-minute-walk and forced-vital-capacity outcomes to alglucosidase alfa in the COMET trial, but GCC adoption remains nascent: NPHC has not established criteria for switching adequately-responding patients from Lumizyme, so access runs through individual case submission rather than standing formulary approval. Sanofi is pursuing NPHC inclusion for Nexviazyme as a first-line ERT option, which would bypass the switch-criteria requirement entirely. Cipaglucosidase alfa plus miglustat, FDA-approved in 2023, is not yet SFDA-registered, giving Nexviazyme a multi-year runway before a third mechanism arrives.

Next-gen ERT beats the 2006 standard clinically but still can't get a formulary switch.

Five questions this report answers:

Q1 - What NPHC criteria govern switching an adequately-responding LOPD patient to avalglucosidase alfa?

Q2 - How is Saudi Arabia's 2021 newborn-screening expansion changing the infantile-onset ERT pipeline?

Q3 - When will cipaglucosidase alfa plus miglustat reach SFDA registration, and what window does that leave Nexviazyme?

Q4 - Why hasn't Nexviazyme displaced Lumizyme as first-line ERT despite superior COMET trial outcomes?

Q5 - How does individual case submission work today for GCC patients seeking avalglucosidase alfa?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PompeDisease #GCC #RareDisease #EnzymeReplacementTherapy #MarketAccess

Live report page:  https://axlrx.ai/pompe-disease/gcc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/